Translate Bio Inc (Translate Bio), formerly RaNA Therapeutics Inc, is a healthcare service provider that develops therapies targeting RNA within cells in the body to selectively activate protein expression. The company provides platform oligonucleotides (oligos) are molecules designed to target specific areas of RNA. Its platform uses two distinct approaches to activate RNA during transcription and post-transcription. Translate Bio provides target treatment areas such as spinal muscular atrophy and friedreich’s ataxia. It offers other target treatment areas such as musculoskeletal disease, inflammatory disease and liver disease. The company provides investment partners such as Atlas Venture, Monsanto, MS Ventures, Omega Funds, Partners Innovation Fund, Pfizer Venture Investments and SR One, among others. Translate Bio is headquartered in Lexington, Massachusetts, the US
Headquarters
United States of America
Address
29 Hartwell Ave, Lexington, Massachusetts, 02421-3102
Website
translate.bio
Telephone
1 617 9457361
No of Employees
122
Industry
Pharmaceuticals and Healthcare
Revenue (2020)
$138.8M
Explore premium data & analytics
Products and Services
| Products |
|---|
| Technology Platform |
| Oligonucleotide |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2021 | Ownership Changes | In September, the company was acquired by Sanofi, a pharmaceutical industry company. |
| 2021 | Others | In June, the company and Sanofi Pasteur initiated a Phase 1 clinical trial evaluating an mRNA-based investigational vaccine against seasonal influenza. |
| 2020 | Contracts/Agreements | In March, the company and Sanofi's vaccines global business unit, Sanofi Pasteur collaborated with the Translate Bio for the development of a novel messenger RNA (mRNA) vaccine for COVID-19. |
Competitor Comparison
| Key Parameters | Translate Bio Inc | Cellular Biomedicine Group Inc | Gotham Therapeutics Corp | Novartis Gene Therapies | ReveraGen BioPharma Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Lexington | Rockville | New York City | Bannockburn | Rockville |
| State/Province | Massachusetts | Maryland | New York | Illinois | Maryland |
| No. of Employees | 122 | 217 | - | - | 11 |
| Entity Type | Private | Private | Private | Private | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Daniel Lynch | Chairman | Executive Board | 2012 | 62 |
| Ronald C. Renaud, Jr. | Chief Executive Officer; Director | Executive Board | 2014 | 52 |
| Brendan Smith | Corporate Strategy; Chief Financial Officer | Senior Management | 2021 | - |
| Paul Burgess | Chief Operating Officer; Chief Legal Officer; Secretary | Senior Management | 2016 | 47 |
| Frank DeRosa | Chief Technology Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer